Glucagon-Like Peptide 1 – Page 2 – Talk Bio

Actionable Insights Powered by AI

Eli Lilly Vows Vigorous Defense as Texas Sues Over Alleged Drug Kickbacks

1 month ago talkbio0Tagged Drug Prescriptions, eli lilly, Free Nurse Program ', Glucagon-Like Peptide 1, Ken Paxton, kickback scheme, Medicaid fraud, Mounjaro, pharmaceutical litigation, Support Services Program, Texas, Zepbound

Eli Lilly; Texas Attorney General; kickback scheme; drug prescriptions; Mounjaro; Zepbound; GLP-1 drugs; Medicaid fraud; Free Nurse Program; Support Services Program; Ken Paxton; pharmaceutical litigation

Obesity Leaders Dig Manufacturing Moats To Defend Injectable GLP-1 Empires

1 month ago talkbio0Tagged Bariatric Surgery, biosimilars/generics, Capital Expenditures, China, competition, constraints, eli lilly, GLP-1 pipeline, Glucagon-Like Peptide 1, manufacturing capacity, Market, Medicare, Nordisk, Obesity, Policy, Risk, Wegovy, Zepbound

GLP-1; manufacturing capacity; Eli Lilly; Novo Nordisk; obesity drugs; Wegovy; Zepbound; capital expenditures; supply constraints; market competition; Medicare coverage; policy risk; biosimilars/generics; China GLP-1 pipeline; bariatric surgery

Novo Nordisk Maintains Edge in Obesity Pill Race as Lilly’s Pill Shows Modest Results

1 month ago talkbio0Tagged competition, Contraceptives, Oral, eli lilly, Glucagon-Like Peptide 1, Market, Nordisk, Obesity, oral semaglutide, orforglipron, Wegovy, Weight-Loss Agents, Zepbound

Novo Nordisk; Eli Lilly; obesity pill; oral semaglutide; orforglipron; weight loss drugs; Wegovy; Zepbound; GLP-1; market competition

Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data

1 month ago talkbio0Tagged earnings, Eli, Eli Lilly, Expectations, franchise, Glucagon-Like Peptide 1, Obesity, Oral cavity, orforglipron, Q2 2025, regulatory submission, Weight Loss

Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations

Execution, Execution, Execution: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

1 month ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, Incretins, Leadership Change, Market, Maziar Mike Doustdar, Nordisk, Obesity, Ozempic, pipeline, Wegovy

Novo Nordisk; Maziar Mike Doustdar; obesity; diabetes; pipeline cuts; GLP-1 drugs; Wegovy; Ozempic; incretin market; leadership change

Terns to Stop Funding Metabolic Disease Trials Beyond 2025; Seeks Partners for Assets

1 month ago talkbio0Tagged agonists, Clinical Trials, Glucagon-Like Peptide 1, Metabolic Diseases, Myeloid Leukemia, Chronic, Oncology Focus, Partnering, Pipeline Strategy, TERN-601, TERN-701, Terns

Terns Pharmaceuticals; metabolic disease; clinical trials; pipeline strategy; partnering; oncology focus; TERN-601; TERN-701; GLP-1 agonists; CML

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

1 month ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

China Approves Lilly and Innovent’s Mazdutide, Marking New Era for GLP-1 Obesity Drugs

3 months ago talkbio0Tagged China approval, eli lilly, GCG, GCG/GLP-1 agonist, Glucagon-Like Peptide 1, Innovent Biologics, mazdutide, N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide, Obesity, Weight maintenance regimen

Mazdutide; China approval; Innovent Biologics; Eli Lilly; GLP-1 obesity drugs; dual GCG/GLP-1 agonist; NMPA; weight management

Altimmune’s Incretin Misses Fibrosis Improvement Endpoints in MASH Trial

3 months ago talkbio0Tagged Altimmune, Clinical Trials, Fibrosis, Glucagon-Like Peptide 1, Incretins, MASH, pemvidutide

Altimmune; incretin; pemvidutide; fibrosis; MASH; GLP-1; clinical trial

Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal

3 months ago talkbio0Tagged deceptive marketing, Glucagon-Like Peptide 1, Hims & Hers, Nordisk, partnership termination, stock plunge, Telemedicine, Wegovy, Weight-Loss Agents

Hims & Hers; stock plunge; Novo Nordisk; Wegovy; partnership termination; compounded GLP-1 drugs; deceptive marketing; telehealth; weight loss drugs